Findings suggest clinicians view these drugs as safe and effective in this population, yet gaps in equitable care remain for those with schizophrenia.
September 3, 2026
In a significant shift for public health policy and clinical practice, new research has revealed that adults living with serious mental illness (SMI) are now being prescribed glucagon-like peptide-1 (GLP-1) receptor agonists at higher rates than the general population. This trend, observed across U.S. insurance claims data from 2018 to 2024, marks a pivotal moment in the management of metabolic health for individuals with conditions such as bipolar disorder, major depressive disorder, and schizophrenia.
The findings, published in JAMA Psychiatry, offer a glimmer of hope in addressing a long-standing health disparity: the 10- to 20-year gap in life expectancy that individuals with SMI face compared to the general population—a disparity driven largely by preventable cardiovascular and metabolic complications.
Main Facts: A Shift in Prescribing Patterns
The study, led by Emma McGinty, PhD, MS, of Weill Cornell Medicine, analyzed a massive dataset of over 104 million adults. The primary takeaway is clear: among patients with clinical indications for GLP-1 medications—such as type 2 diabetes or obesity—those diagnosed with SMI were more likely to receive a prescription for these high-demand drugs than their counterparts without mental health diagnoses.
This result was initially surprising to the research team. Historically, individuals with SMI have faced significant barriers to accessing guideline-concordant medical care. They are often less likely to receive preventative screenings, oncology care, or aggressive cardiovascular interventions, a phenomenon often exacerbated by the complexities of navigating insurance systems like Medicaid.
"Our findings support the idea that clinicians view these medications as safe and effective for people with SMI," Dr. McGinty told MedPage Today. This clinical confidence signals a departure from previous eras, where clinicians may have been hesitant to introduce complex, injectable medications to patients managing the stability of psychiatric symptoms.
Chronology: From Regulatory Scrutiny to Widespread Acceptance
The path to the current, relatively high utilization of GLP-1s in this population was not without turbulence. The journey has been defined by a tense interplay between clinical need and regulatory caution.
- 2018–2022: As GLP-1 agonists like semaglutide and tirzepatide gained mainstream prominence for weight loss and glucose management, early adopters began using them off-label for patients with antipsychotic-induced weight gain—a common and debilitating side effect of many psychiatric medications.
- Early 2024: A period of heightened caution emerged when the U.S. Food and Drug Administration (FDA) launched a preliminary review into potential signals of suicidal ideation associated with GLP-1 use. During this window, some clinicians paused new prescriptions for patients with existing mental health diagnoses, fearing the exacerbation of psychiatric symptoms.
- January 2026: Following extensive real-world evidence and safety evaluations, the FDA concluded that there was no credible causal link between GLP-1 agonists and suicidal behavior. The agency officially requested that manufacturers remove warning language regarding suicidal ideation from drug labels.
- 2026 (Present): With the "safety shadow" lifted, the current analysis confirms that prescribing rates have rebounded and accelerated, showing that the medical community has largely embraced these drugs as essential tools for the SMI population.
Supporting Data: Understanding the Population
The scale of the study underscores the severity of the metabolic burden within the SMI community. The researchers analyzed Inovalon Insights Real-World Data, covering commercial, Medicare Advantage, and Medicaid Managed Care beneficiaries.
Prevalence of Comorbidities
The data highlighted a stark reality regarding the health profile of those with SMI:
- Diabetes: 22.4% in the SMI group compared to 11.5% in the non-SMI group.
- Obesity: 42.9% in the SMI group compared to 21.8% in the non-SMI group.
- Sleep Apnea: 17% in the SMI group compared to 6.3% in the non-SMI group.
The Schizophrenia Exception
Despite the overall positive trend, the researchers identified a concerning caveat. Among adults with diabetes, those specifically diagnosed with schizophrenia had lower GLP-1 prescription rates (rising from 3.4% in 2018 to 19.4% in 2024) compared to those without SMI (4.5% in 2018 to 23.1% in 2024).
This disparity suggests that while the broader SMI category is seeing increased access, patients with schizophrenia may still face unique hurdles. These might include difficulty in coordinating care between psychiatrists and primary care physicians, or the systemic failure to adequately monitor metabolic health in patients who are often marginalized within the healthcare infrastructure.
Official Responses and Clinical Perspectives
The medical community has received these findings as a validation of integrated care. Dr. McGinty and her colleagues emphasized that GLP-1s represent a "transformative" opportunity for cardiovascular risk prevention.
"Extant evidence suggests GLP-1s effectively treat indicated conditions among people with SMI, including those using antipsychotic medications, without adverse psychiatric effects," the authors stated in their report.
For many patients, these drugs do more than manage blood sugar; they mitigate the weight gain associated with second-generation antipsychotics, which has long been a primary reason for medication non-adherence. By addressing the physical side effects of psychiatric treatment, clinicians may inadvertently improve psychiatric outcomes, as patients are more likely to continue their prescribed mental health regimens when they do not feel the physical toll of metabolic distress.
However, the authors remain cautious. They recommend that these medications should not be viewed as a panacea but as part of a "comprehensive care" model. This model includes:
- Behavioral Lifestyle Changes: Sustained counseling and nutritional support.
- Pharmacological Augmentation: The use of other agents, such as metformin, for those where GLP-1s may not be the initial or only line of defense against antipsychotic-induced weight gain.
Implications for Future Care and Policy
The findings hold significant implications for both healthcare policy and future clinical research.
1. Addressing the Equity Gap
The "schizophrenia exception" identified in the study is a clear call to action. Targeted outreach programs are required to ensure that patients with the most severe mental health conditions are not left behind in the "GLP-1 revolution." This requires better integration of primary care services into community mental health centers.
2. The Need for Longitudinal Research
While the current study captures a six-year trajectory, it does not answer how long these patients stay on the medication. Given the chronic nature of metabolic diseases and SMI, understanding "persistence"—how long a patient remains on therapy—is critical. Discontinuation rates in the SMI population could be higher due to issues with medication costs, pharmacy access, or the need for consistent injection administration.
3. Regulatory and Insurance Reform
Because the study did not capture out-of-pocket costs, it remains unclear how much of the prescribing gap is dictated by insurance coverage hurdles. For Medicaid beneficiaries, who constitute a large portion of the SMI population, prior authorization requirements for GLP-1s can be notoriously difficult to navigate. Policymakers should consider whether these administrative burdens disproportionately impact the SMI population, further entrenching health inequities.
Conclusion
The rapid adoption of GLP-1 receptor agonists for individuals with SMI represents a triumph of modern medicine over historical health disparities. By effectively treating the physical comorbidities that have plagued this population for decades, clinicians are helping to close the mortality gap.
However, as Dr. McGinty and her team conclude, the work is far from finished. The challenge for the coming years will be to refine these prescribing practices, ensure equitable access for the most vulnerable subsets of the SMI population, and integrate these potent new therapies into a holistic, patient-centered approach to mental and physical health. As the medical field moves forward, the focus must shift from simply "prescribing" to "sustaining" long-term, equitable care for all.
